Identifying Biomarkers for Recurrent CDI and Post-CDI IBS

Overview

About this study

The goal of this study is to identify risk factors and biomarkers for recurrent C. difficile infection and post-C. difficile infection irritable bowel syndrome. We will study patient characteristics and study stool samples to investigate if bile acid composition, microbiome profile, and end-of-treatment toxin PCR has a relationship to either recurrent C. difficile infection or post-infectious irritable bowel syndrome.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Adult patients ≥ 18 years of age with first or index episode of CDI.

Exclusion Criteria:

  • Patients with prior history of CDI, uncontrolled IBS, or history of inflammatory bowel disease.

 

 

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Rochester, Minn.

Mayo Clinic principal investigator

Sahil Khanna, M.B.B.S., M.S.

Closed for enrollment

More information

Publications

Publications are currently not available

Additional contact information

Non-cancer trials contact form

Phone: 800-664-4542 (toll-free)

International patient clinical studies questions